Columbia Care Launches “100,000,000 Ways to Break the Opioid Crisis” Initiative

Columbia Care to partner with experts at Montefiore Medical Center
and Albert Einstein College of Medicine for initial phase of nationwide
study on medical cannabis’s impact on opioid use for pain

NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (“Columbia Care”, or the “Company”) (NEO: CCHW), a
leading international medical cannabis company, today announced the
launch of its new initiative, “100,000,000 Ways to Break the Opioid
Crisis,” a nationwide effort to test whether precisely-formulated
medical cannabis can be a safe and effective alternative to opioids for
pain.

Columbia Care is kicking off the “100,000,000 Ways to Break the Opioid
Crisis” initiative by providing its precisely-formulated
pharmaceutical-quality cannabis-based medicines for a precedent-setting
study to determine whether medical cannabis can reduce participants’
dependence on opioid use in managing pain. This study, which is being
conducted at Montefiore Medical Center and Albert Einstein College of
Medicine in the Bronx, will add to the body of knowledge to inform
healthcare practices and public policies in this arena. The study is
expected to be expanded to other hospitals throughout New York State
and, ultimately, to other states where Columbia Care’s formulated
medical cannabis products are also available.

Renowned addiction experts Dr. Chinazo Cunningham and Dr. Julia Arnsten,
who are both researchers at Montefiore and Einstein, are leading the
study.

“Despite the fact that millions of Americans experience chronic pain,
physicians have few treatment options for these patients beyond opioids.
Patients are often faced with a difficult choice, to either live with
their chronic pain or risk developing an opioid use disorder,” said Dr.
Cunningham.

Dr. Arnsten added, “Conducting this study will enable us to tightly
control cannabinoid doses, which is critical to gathering data. This
study reflects our commitment at Montefiore and Einstein to explore
all potentially therapeutic options to relieve symptoms for all
patients, especially patients with chronic pain. We are proud to be
working with a partner like Columbia Care.”

Rosemary Mazanet, M.D., Ph.D., Chief Scientific Officer and Chair of the
Scientific Advisory Board at Columbia Care continued, “We are honored to
collaborate with experts at Montefiore and Einstein on this
groundbreaking, large and rigorous scientific study needed to
definitively determine whether cannibas-based medicines can be an
alternative for opioid use for pain. It’s rare to participate in an
initiative that has the potential to save lives, reduce healthcare costs
and empower individuals with the freedom of choice – it’s very exciting.”

About Columbia Care Inc.

Columbia Care is one of the United States’ largest and most experienced
cultivators, manufacturers and providers of medical cannabis products
and services, having completed more than 750,000 successful sales
transactions since its inception. Columbia Care is a patient-centered
health and wellness company setting the standard for compassion,
professionalism, quality, caring and innovation, working in
collaboration with some of the most renowned and innovative teaching
hospitals and medical centers in the world. The Company is committed to
providing the type of education and transparency patients deserve and
quality of product that clinicians expect. For more information on
Columbia Care, please visit www.col-care.com.

Forward Looking Statements

This press release contains “forward-looking information” within the
meaning of applicable Canadian securities legislation which are based
upon Columbia Care’s current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified by the use of
forward-looking terminology such as “expect”, “likely”, “may”, “will”,
“should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate”
and other similar words, including negative and grammatical variations
thereof, or statements that certain events or conditions “may”, “would”
or “will” happen, or by discussions of strategy. Forward-looking
information include estimates, plans, expectations, opinions, forecasts,
projections, targets, guidance or other statements that are not
statements of fact. Any forward-looking information speaks only as of
the date on which it is made, and, except as required by law, Columbia
Care does not undertake any obligation to update or revise any
forward-looking information, whether as a result of new information,
future events or otherwise. New factors emerge from time to time, and it
is not possible for Columbia Care to predict all such factors. When
considering these forward-looking statements, readers should keep in
mind the risk factors and other cautionary statements in Columbia Care’s
final prospectus dated March 21, 2019 and filed with the applicable
Canadian securities regulatory authorities on SEDAR at www.sedar.com.
The risk factors and other factors noted in Columbia Care’s final
prospectus could cause actual events or results to differ materially
from those described in any forward-looking information.

Contacts

Investor:
Investor Relations
+1.212.271.0915
[email protected]

Media:
Josephine
Belluardo, Ph.D.
LifeSci Public Relations
+1.646.751.4361
[email protected]